Riverview Trust Co Sells 12,295 Shares of Pfizer Inc. $PFE

Riverview Trust Co lessened its position in Pfizer Inc. (NYSE:PFE) by 74.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,119 shares of the biopharmaceutical company’s stock after selling 12,295 shares during the quarter. Riverview Trust Co’s holdings in Pfizer were worth $100,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in PFE. Brighton Jones LLC increased its stake in Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after acquiring an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC grew its stake in shares of Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after buying an additional 2,087 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of Pfizer by 4,183.6% during the first quarter. GAMMA Investing LLC now owns 1,599,742 shares of the biopharmaceutical company’s stock valued at $40,537,000 after buying an additional 1,562,396 shares during the last quarter. Merit Financial Group LLC grew its stake in shares of Pfizer by 24.1% during the first quarter. Merit Financial Group LLC now owns 158,871 shares of the biopharmaceutical company’s stock valued at $4,026,000 after buying an additional 30,904 shares during the last quarter. Finally, RFG Advisory LLC grew its stake in shares of Pfizer by 41.2% during the first quarter. RFG Advisory LLC now owns 70,409 shares of the biopharmaceutical company’s stock valued at $1,784,000 after buying an additional 20,546 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of NYSE PFE opened at $27.21 on Thursday. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $30.43. The company has a 50 day simple moving average of $24.59 and a two-hundred day simple moving average of $24.14. The company has a market capitalization of $154.68 billion, a price-to-earnings ratio of 14.47, a P/E/G ratio of 0.82 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter last year, the firm earned $0.60 earnings per share. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Wall Street Analyst Weigh In

PFE has been the topic of a number of recent research reports. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday. Morgan Stanley raised their price objective on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 6th. Bank of America raised their price objective on Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Citigroup increased their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Finally, UBS Group reiterated a “neutral” rating and set a $28.00 target price on shares of Pfizer in a report on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Pfizer has an average rating of “Hold” and an average target price of $28.29.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.